Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocyte leukemia

Massimo Breccia; Giuseppe Cimino; Daniela Diverio; Fabiana Gentilini; Franco Mandelli; Francesco Lo Coco

doi:10.3324/haematol.11329

Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocyte leukemia

Massimo Breccia, Giuseppe Cimino, Daniela Diverio, Fabiana Gentilini, Franco Mandelli, Francesco Lo Coco

Fondazione Santa Lucia

Research output: Contribution to journal › Article › peer-review

Abstract

We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m²) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.

Original language	English
Pages (from-to)	1273-1274
Number of pages	2
Journal	Haematologica
Volume	92
Issue number	9
DOIs	https://doi.org/10.3324/haematol.11329
Publication status	Published - Sep 2007

Keywords

Acute promyelocytic leukemia
Gentuzumab ozogamicin
Molecular relapse

ASJC Scopus subject areas

Hematology

Access to Document

10.3324/haematol.11329

Cite this

@article{aa85820a164e44b286e46566e70612ce,

title = "Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocyte leukemia",

abstract = "We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m2) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.",

keywords = "Acute promyelocytic leukemia, Gentuzumab ozogamicin, Molecular relapse",

author = "Massimo Breccia and Giuseppe Cimino and Daniela Diverio and Fabiana Gentilini and Franco Mandelli and {Lo Coco}, Francesco",

year = "2007",

month = sep,

doi = "10.3324/haematol.11329",

language = "English",

volume = "92",

pages = "1273--1274",

journal = "Haematologica",

issn = "0390-6078",

publisher = "NLM (Medline)",

number = "9",

}

TY - JOUR

T1 - Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocyte leukemia

AU - Breccia, Massimo

AU - Cimino, Giuseppe

AU - Diverio, Daniela

AU - Gentilini, Fabiana

AU - Mandelli, Franco

AU - Lo Coco, Francesco

PY - 2007/9

Y1 - 2007/9

N2 - We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m2) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.

AB - We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m2) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.

KW - Acute promyelocytic leukemia

KW - Gentuzumab ozogamicin

KW - Molecular relapse

UR - http://www.scopus.com/inward/record.url?scp=36349001200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36349001200&partnerID=8YFLogxK

U2 - 10.3324/haematol.11329

DO - 10.3324/haematol.11329

M3 - Article

C2 - 17768126

AN - SCOPUS:36349001200

VL - 92

SP - 1273

EP - 1274

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 9

ER -

Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocyte leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this